Kalaris Therapeutics
KLRS
85 hedge funds and large institutions have $294M invested in Kalaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 16 closing their positions.
168% more capital invested
Capital invested by funds: $110M → $294M (+$184M)
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
48% more call options, than puts
Call options by funds: $267K | Put options by funds: $180K
1% more funds holding
Funds holding: 84 → 85 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0.13% less ownership
Funds ownership: 1.87% → 1.74% (-0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$22M |
| 2 |
Alkeon Capital Management
New York
|
+$14.7M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$7.35M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
+$5.88M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.13M |
| 2 |
Goldman Sachs
New York
|
-$375K |
| 3 |
Barclays
London,
United Kingdom
|
-$367K |
| 4 |
Two Sigma Investments
New York
|
-$304K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$293K |
KLRS Hedge Fund Activity: Q3 2022 in Review
85 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2022, worth a combined $294M — up 168% from $110M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KLRS positions and 16 closed out — a net gain of 1 holder — while 34 added to existing stakes and 22 trimmed.
The largest buyer was Artal Group, adding an estimated $22M. The largest seller was JP Morgan Chase, cutting an estimated $1.13M.
- 85 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2022, up from 84 in Q2 2022.
- Funds reported $294M of Kalaris Therapeutics stock for Q3 2022, up 168% quarter-over-quarter.
- 17 funds opened new Kalaris Therapeutics positions in Q3 2022 and 16 closed out, a net change of +1 holder.
- The largest Kalaris Therapeutics buyer in Q3 2022 was Artal Group, an estimated $22M added.
- The largest Kalaris Therapeutics seller in Q3 2022 was JP Morgan Chase, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2022.